Wave Life Sciences Ltd

GSK has entered a collaboration with Wave Life Sciences to advance a GalNAc-siRNA hepatology candidate into its development pipeline, while separately expanding its tuberculosis research with AN2 Therapeutics. The Wave Life Sciences partnership focuses on RNA-based therapies targeting liver diseases using GalNAc-siRNA technology, giving GSK another modality in liver disease and access to Wave's SpiNA design platform without building that RNA chemistry capability internally. The AN2 Therapeutics work is supported by new funding from the Bill & Melinda Gates Foundation for boron-based drug discovery. The Wave hepatology move and the Gates-backed TB research funding sit within GSK's existing narrative of heavier R&D reinvestment and business development, though the high R&D spend and execution uncertainty still apply if these programs move slowly or fail to produce strong late-stage assets. The clearest next marker will be whether GSK or Wave disclose that one of the three remaining collaboration programs reaches formal candidate selection over the next research updates, triggering further milestone payments.

Wave Life Sciences has initiated the Phase 2a portion of its INLIGHT trial evaluating WVE-007, an investigational GalNAc-siRNA therapy, in people with obesity and related metabolic conditions. The placebo-controlled, multidose study enrolls patients with a body mass index of 35 to 50 kilograms per square meter and comorbidities including type 2 diabetes, building on Phase 1 results where a single 240-milligram dose reduced visceral fat by 14 percent, total fat by 5 percent, and waist circumference by 3 percent at six months while preserving muscle mass. WVE-007 has been generally safe and well tolerated up to 600 milligrams, with data supporting once- or twice-yearly dosing, and the Phase 2a portion is expected to show further improvements in body composition, weight loss, and cardiometabolic biomarkers. Chief Medical Officer Christopher Wright noted that a 10 percent reduction in visceral fat can lower the risk of developing type 2 diabetes by 28 percent even a decade later, and the company plans to start additional Phase 2 trials in the second half of 2026, including studies combining WVE-007 with incretins and as post-incretin maintenance therapy.